Cite
MLA Citation
Philipp Harter et al.. “2022-RA-1074-ESGO AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer.” International journal of gynecological cancer, vol. 32, n.d., pp. A294–A295. http://access.bl.uk/ark:/81055/vdc_100168339599.0x000043